Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Follow-up Phase II Open-label Study to Evaluate the Long-term Safety and Efficacy Profile of ABX464 Given at 25 mg Once Daily in Subjects With Moderate to Severe Active Ulcerative Colitis

NCT05177835 is registered in ClinicalTrials.gov with Abivax S.A. as lead sponsor.

NCT NCT05177835
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05177835 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Follow-up Phase II Open-label Study to Evaluate the Long-term Safety and Efficacy Profile of ABX464 Given at 25 mg Once Daily in Subjects With Moderate to Severe Active Ulcerative Colitis
Lead sponsor
Abivax S.A.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 3, 2021
Completion date
April 30, 2028
Enrollment
203 (estimated)
Sites
46

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis